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Abstract
Background: To compare response to antidepressants between randomized controlled trials (RCTs) and observational trials.
Methods and Findings: Published and unpublished studies (from 1989 to 2009) were searched for by 2 reviewers on
Medline, the Cochrane library, Embase, clinicaltrials.gov, Current Controlled Trial, bibliographies and by mailing key
organisations and researchers. RCTs and observational studies on fluoxetine or venlafaxine in first-line treatment for major
depressive disorder reported in English, French or Spanish language were included in the main analysis. Studies including
patients from a wider spectrum of depressive disorders (anxious depression, minor depressive episode, dysthymia) were
added in a second analysis. The main outcome was the pre-/post-treatment difference on depression scales standardised to
100 (17-item or 21-item Hamilton Rating Scale for Depression or Montgomery and A ˚sberg Rating Scale) in each study arm. A
meta-regression was conducted to adjust the comparison between observational studies and RCTs on treatment type, study
characteristics and average patient characteristics. 12 observational studies and 109 RCTs involving 6757 and 11035 patients
in 12 and 149 arms were included in the main analysis. Meta-regression showed that the standardised treatment response in
RCTs is greater by a magnitude of 4.59 (2.61 to 6.56). Study characteristics were related to standardised treatment response,
positively (study duration, number of follow-up assessments, outpatients versus inpatients, per protocol analysis versus
intention to treat analysis) or negatively (blinded design, placebo design). At patient level, response increased with baseline
severity and decreased with age. Results of the second analysis were consistent with this.
Conclusions: Response to antidepressants is greater in RCTs than in observational studies. Observational studies should be
considered as a necessary complement to RCTs.
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Introduction
Antidepressant drugs have become the cornerstone of the
treatment of major depressive disorder (MDD). Recently, three
meta-analyses questioned this picture, emphasising the number of
non-published negative studies [1] and the importance of the
placebo response in mild to moderate depressive disorders [2,3].
Placebo response has increased significantly in recent years [4], it
has been related to intensive follow-up by trained teams [5], linked
to the probability of receiving a placebo [6], and found to depend
on the characteristics of the population included [7]. To cope with
this phenomenon, some randomized controlled trials (RCTs)
exclude placebo responders on the basis of a one-week placebo
run-in period [8], and use strict inclusion criteria [9].
Thus, experimental conditions that enhance internal validity to
prove antidepressant efficacy can modify the effect demonstrated.
They do not correspond to antidepressant use in real life [10], and
decrease the external validity of such studies.
The determination of effectiveness is part of the post-listing
assessment process, via observational studies. In the cardiovascular
field, some authors have worked on the link between randomized
controlled trials and observational studies [11]; in psychiatry this
has been applied to psychotherapy [12], but, to our knowledge,
nobody has explored this issue for antidepressants.
To quantify the links between antidepressant efficacy and
effectiveness we reviewed RCTs and observational trials in MDD
first line treatment using fluoxetine, the first selective serotonin
reuptake inhibitor available on the market which has become a
reference drug and venlafaxine a serotonin-norepinephrine reuptake
inhibitor which was the first antidepressant in terms of sales in 2008
[13]. The main objective was to compare observed response to
antidepressants in RCTs with response in observational trials. Over a
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synthesise and quantify the impact of all methodological choices on
the measurement of antidepressant response: blind design, placebo
design, year of publication, number of follow up assessments, type of
analysis, exclusion of placebo responders and patients’ characteristics
as baseline severity.
Methods
The methods of this meta-analysis on aggregated data and the
inclusion criteria were pre-specified and documented in a written
protocol.
Eligibility criteria
Types of participants. In the main analysis, we reviewed
studies involving adults with a diagnosis of MDD (DSM IV, DSM
IV-R, DSM III, DSM III-R, ICD 10, Feighner criteria, Research
Diagnostic Criteria). Studies involving patients with other
psychiatric or medical comorbidities were considered, except if
these comorbidities were an explicit inclusion criterion for the
study. Studies involving more than 20% bipolar disorder were
excluded, as were studies exclusively involving elderly patients or
patients with seasonal affective disorder, post partum depression,
postmenopausal depression, atypical depression.
As in ‘‘real-life’’ a wide range of depressive disorders is treated
with antidepressants, a second analysis included studies involving
patients with a diagnosis of anxious depression (criteria for both an
anxious disorder and MDD) and/or minor depressive episode
and/or dysthymia.
Types of intervention. We focused our attention on
fluoxetine and venlafaxine in oral mono-therapy for MDD first-
line treatment. By choosing these two antidepressants, which are
widely used, we were sure to have a large number of RCTs and
observational studies.
Types of outcome. The primary outcome measure was the
difference between baseline and last assessment on the 17-item or
21-item Hamilton Rating Scale for Depression (HRSD) or the
Montgomery and A ˚sberg Rating Scale (MADRS).
Studies not providing the desired information on these scales
were included in the qualitative review.
Types of study. In this review the studies considered were
those designed to measure antidepressant efficacy or effectiveness,
conducted between January 1989 and July 2009: on the one hand
RCTs (antidepressant versus placebo or active treatment) and on
the another hand observational cohorts (longitudinal non-
randomized and non-blinded studies). Studies designed to
provide evidence on other issues such as physiological
hypotheses were not retained. Only study reports in English,
French and Spanish language were considered.
Search strategy
Eligible studies were identified from Pubmed/Medline, the
Cochrane library, and Embase, including conference abstracts. In
a first step, an initial search on Medline was undertaken to
determine optimal keywords and include possible changes in the
databases. The keywords used were double-checked before
starting the main search. In a second step all identified keywords
were used to search all the databases mentioned above. A third
search was undertaken on the bibliographies of identified articles
and previous meta-analyses. The initial keywords used were:
Depressive Disorder NOT Depression, Postpartum NOT Season-
al Affective Disorder; Antidepressive Agents; Fluoxetine; Venla-
faxine.
Unpublished studies were sought by communication with key
researchers and key organizations (Food and Drug Administration
and European Medicines Agency). A search on clinicaltrials.gov
and Current Controlled Trial was also performed.
Study selection
Eligibility assessment was performed independently in blinded
standardized manner by 2 reviewers. Studies identified were
grouped into two categories: RCTs and observational cohorts.
Disagreements were resolved by consensus or in consultation with
a third reviewer.
Studies appearing to duplicate authors, treatment comparisons,
sample sizes and outcomes were checked one against another to
avoid double-counting and integrating data from several reports
on the same study.
Assessment of Methodological Quality
Each paper was then assessed for methodological quality prior
to inclusion in the review, using two appropriate standardized
critical appraisal instruments [14], one for RCTs and one for
observational studies (Appendix S1).
Data Collection
A data extraction sheet based on the Cochrane Handbook for
Systematic Reviews of Interventions guidelines Version 5.0.2 [15]
was developed, pilot-tested on ten randomly-selected included
studies, and refined accordingly. For each arm of the studies
included, information was extracted on: 1/characteristics of the
study (year, country, randomized or not? blinded or not? versus
placebo or not? exclusion of patients on the basis of a placebo
washout period or not? number of follow-up visits, number of
arms, funding); 2/characteristics of trial participants (age, gender,
number of patients included in analysis, type [inpatient (including
studies with both inpatients and outpatients), outpatient and
primary-care outpatient]); 3/type of intervention (treatment, dose,
duration); 4/outcome measure (scale used, pre- and post-
treatment mean and SD, type of analysis). Dosages were classified
as ‘‘low’’, ‘‘medium’’, and ‘‘high’’ [16] (Table 1) or ‘‘variable’’.
One review author extracted these data from the studies
included. The second author extracted the data from 10% of the
studies to have an idea of the inter-rater reliability, and checked
the data in the remaining studies. Authors of reviewed articles
were contacted for further information and were asked for missing
data when it was needed.
Data analysis
The main criterion was the pre-/post-treatment difference on
the depression scale in each study arm involving venlafaxine or
fluoxetine or placebo. Taking into account the numerous criticisms
on the use of effect sizes in meta-analyses [17,18], we standardised
the different instruments (mean and SD) by multiplying the scores
by 100 and dividing them by the difference between the maximum
possible value minus the minimum possible value, so that
standardised scores range from 0 to 100. Then we calculated the
Table 1. Dosage classification.
Low Medium High
Fluoxetine ,30 mg/day 30–50 mg/day .50 mg/day
Venlafaxine ,153 mg/day 153–218,7 mg/day .218,7 mg/day
doi:10.1371/journal.pone.0020811.t001
RCT vs. Observational Studies on Antidepressants
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reported in papers without corresponding estimates of variance,
this variance was calculated from pre- and post-treatment
variances when possible (using a pre-post- correlation estimated
from the other studies). Heterogeneity between comparable studies
was assessed using the Q statistic [19]. Publication bias was
investigated graphically using funnel plots.
To adjust our comparison of observational studies and
randomized controlled trials on identified sources of heterogeneity,
and to quantify the impact of methodological choices on response,
a meta-regression was performed. The dependent variable was D
and the following explanatory variables were pre-specified: type of
treatment (fluoxetine, venlafaxine, placebo); year of publication;
depression scale used (HRSD-17, HRSD-21, MADRS); study
duration; randomisation (yes/no); placebo design (yes/no);
number of assessments; exclusion of placebo responders (yes/no);
age; gender; patient type (outpatients in primary care/outpatients/
inpatients); type of analysis (per protocol/intention to treat with
last observation carried forward); baseline severity. This meta-
regression was performed with the ‘‘study’’ factor specified as a
random effect (mixed model). Studies were weighted by the inverse
of D variance (n/var). Multiple imputation of missing data was
performed using a Gibbs sampler [20].
To assess the robustness of our results, sensitivity analyses were
performed: 1) using a wide range of correlation coefficients
between pre- and post-treatment mean scores on the scale, 2) by
removing each study in turn and 3) using the quality assessment to
adjust the weight of a given study.
Analyses were performed using R (R Development Core Team)
and the libraries meta (Schwarzer G), lme4 (Maechler D), and
MICE (Van Buuren S, Groothuis-Oudshoorn K). Results are
presented according to PRISMA statements [21] and MOOSE
statements [22].
Results
Study selection
The search of Medline, Cochrane and Embase databases
provided a total of 11051 citations with respectively 2985, 3823
and 4243 citations. An additional 66 studies were identified by
manual search. After adjusting for duplicates, 4615 remained.
Of these, 3926 studies were discarded because, after review of
the abstracts, it appeared that these papers did not meet the
criteria. Of 33 unpublished relevant studies identified, only 3
were provided by pharmaceutical firms. 204 studies were
included in the qualitative review and 141 in the quantitative
review (covering the wider range of depressive disorders) with
121 studies in the main analysis. Af l o wc h a r td e t a i l i n gt h es t u d y
selection process for RCTs and observational studies is given in
Figure 1.
Study characteristics and risk of bias within studies
In the main analysis, the studies selected were 12 observational
studies and 109 randomized controlled trials involving respectively
6757 and 11035 patients in 12 and 149 arms. In the depressive
disorder spectrum analysis, the studies selected were 19 observa-
tional studies and 122 randomized controlled trials involving
respectively 15753 and 12405 patients in 19 and 168 arms. A
summary of study methodology, participants, intervention and
quality is given in Table 2 and study characteristics are presented
as a table in a web appendix (Appendix S1).
From 76 letters requesting information sent to authors, we were
able to collect information about missing data for 13 studies.
Results from individual studies and synthesis of results
As expected, using the Q statistic, significant heterogeneity was
detected (p,0.0001) for: 1/active treatment effect in RCTs, 2/
placebo effect in RCTs and 3/active treatment effect in
observational studies. The Forest plot presenting individual study
results is presented in the web appendix (figure S1). Multivariate
meta-regression (Table 3) showed that RCTs overestimate the
standardised treatment response by a magnitude of 4.59 ([95%
confidence interval] 2.61 to 6.56) in the main analysis and by 2.45
(0.97 to 3.93) in the depressive disorder spectrum analysis. In the
main analysis, certain study design factors were associated with
substantial variations in the standardised treatment response. The
increase in treatment response was 0.27 (0.14 to 0.40) for each
additional week of duration, 0.33 (0.11 to 0.55) for each additional
follow-up assessment and 0.07 (0.01 to 0.13) for each year of study
publication. In studies involving outpatients and in those with
outpatients in primary care, patient improvement was respectively
1.81 (0.88 to 2.72) and 3.73 (2.37 to 5.09) greater than
improvement observed in studies involving inpatients. Overesti-
mated treatment response attributable to per-protocol analysis was
2.52 (1.45 to 3.6) when compared to intention-to-treat analysis.
The standardised treatment response was smaller in double-blind
studies than in open-label studies by a magnitude of 5.21 (26.85 to
23.57). Similarly, when there was a placebo arm, treatment
response was smaller by 4.54 (25.50 to 23.58). Regarding
patients, the standardised treatment response increased with mean
baseline severity by 0.78 (0.71 to 0.84) for each percentage value of
the severity scale that was used, and decreased by 0.16 (20.26 to
20.07) for an increase of 1 year in the mean age of patients. The
standardized treatment response for a placebo was 3.35 (23.97 to
22.74) less than the response for fluoxetine, while the treatment
response for venlafaxine was greater than that for fluoxetine by
2.51 (1.88 to 3.14).
Results of the depressive disorders spectrum analysis show the
robustness of our model (Table 3).
To assess the validity of our model we checked that the
Variance Inflation Factor values were under 10 (all were under 3)
and we checked that the normality of the residues was verified.
Risk of bias across studies
Three funnel plots were drawn (Figure 2) for antidepressants in
randomized controlled trials, antidepressants in observational
studies and placebo in randomized controlled trials. The
antidepressant arms in RCTs and in observational studies did
not show evidence of any marked asymmetry whereas the funnel
plot investigating placebo arms in randomized controlled trial
shows some asymmetry.
Additional analysis
Sensitivity analyses using various pre-post treatment correlation
coefficients and taking quality into account showed the robustness
of our estimations.
Sensitivity analysis, removing each study one at a time,
identified a potential outlier among the observational studies
[23]. This is a four-week observational study on fluoxetine in
which the treatment effect is small (3.3 points on the HAMD-17).
When it was removed, the coefficient representing the difference
between randomized controlled trials and observational studies
decreased from 4.59 to 1.67, remaining statistically significant in
the main analysis, and decreased from 2.45 to 1.04 in the
depressive disorder spectrum analysis.
Another potential outlier [24] was noticed among the studies
included in the depressive disorders spectrum analysis. Once it was
removed, the coefficients increased from 2.45 to 4.49. It is
RCT vs. Observational Studies on Antidepressants
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Main analysis (Major depressive disorder) Second analysis (depressive disorder spectrum)
Randomised Controlled
Trials Observational Trials
Randomised
Controlled Trials Observational Trials
Study methodology
Number of studies 109 12 122 19
Year (Min-Max) 1989–2009 1994–2007 1989–2009 1994–2007
Continent (NA=1) (NA=2)
North America (%) 29 (26.8) 5 (41.7) 33 (27.5) 8 (42.1)
Central America and South
America (%)
10 (9.3) 2 (16.7) 11 (9.2) 2 (10.5)
Europe (%) 48 (44.4) 4 (33,3) 55 (45.8) 8 (42.1)
Asia and Oceania (%) 10 (9.3) 1 (8.3) 10 (8.3) 1 (5.3)
Africa (%) 2 (1.9) . 2 (1.7) .
Multi-continent (%) 9 (8.3) . 9 (7.5) .
Blinded
Yes (%) 100 (91.7) . 111 (91.0) .
No (%) 9 (8.3) 12 (100) 11 (9.0) 19 (100)
Placebo design
Yes (%) 22 (20.2) . 26 (21.3) .
No (%) 87 (79.8) 12 (100) 96 (78.7) 19 (100)
Exclusion of placebo responders (NA=10) (NA=3) (NA=11) (NA=3)
Yes (%) 60 (60.6) 1 (11,1) 67 (60.4) 3 (18.7)
No (%) 39 (39.4) 8 (88,9) 44 (39.6) 13 (81.3)
Number of follow-up visits
(Min, Q1, median, Q2, Max)
(NA=2)
2, 5, 6, 7, 13
(NA=1)
2, 4, 5, 7, 10
(NA=2)
2, 5, 6, 7, 13
(NA=1)
2, 4, 5, 7, 14
Study duration (Min, Q1,
median, Q2, Max)
4, 6, 6, 8, 26 4, 8, 8, 17.25, 24 4, 6, 6, 8, 26 4, 8, 8, 20, 24
Quality assessment/100 points
(Min, Q1, median, Q2, Max)
57, 77, 80, 83, 100 54, 58, 62, 71, 75 57, 79, 80, 83, 100 54, 58, 62, 69, 75
Funding (NA=36) (NA=1) (NA=43) (NA=4)
Industry (%) 65 (89.0) 6 (54,5) 69 (87.4) 9 (60)
Mixt (public and industry) (%) 3 (4.1) 3 (27,3) 4 (5.0) 3 (40)
Public (%) 5 (6.9) 2 (18.2) 6 (7.6) 3 (40)
Analysis (NA=4) (NA=3) (NA=5) (NA=6)
ITT with LOCF (%) 72 (68.6) 7 (77.8) 82 (70.1) 10 (76.9)
Per Protocol (%) 33 (31.4) 2 (22,2) 35 (29.9) 3 (23.1)
Arm characteristics
Number of arms 149 12 168 19
Treatment
Fluoxetine (%) 80 (53,7) 5 (41.7) 92 (54.8) 7 (36.9)
Venlafaxine (%) 47 (31.5) 7 (58.3) 50 (29.8) 12 (63.1)
Placebo (%) 22 (14.8) . 26 (15.4) .
Dose (Active treatment arms) (NA=22) (NA=26)
Low (%) 47 (37.0) 5 (41.7) 52 (36.6) 7 (36.8)
Medium (%) 7 (5.5) . 7 (4.9) .
High (%) 8 (6.3) . 8 (5.7) 1 (5.3)
Variable (%) 65 (51,2) 7 (58.3) 75 (52.8) 11 (57.9)
Size (Min, Q1, median, Q2, Max) 10, 37, 62, 95, 320 62, 87.5, 119.5, 395.8, 4320 10, 38.75, 64, 95, 320 14, 70, 96, 407.5, 6719
Patient type (NA=12) (NA=12) (NA=1)
Inpatient (%) 33 (24.1) 1 (8.3) 34 (21.8) 1 (5.6)
Outpatient (%) 93 (67.9) 10 (83.4) 109 (69.9) 15 (83.3)
Primary Care (%) 11 (8) 1 (8.3) 13 (8.3) 2 (11.1)
RCT vs. Observational Studies on Antidepressants
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Main analysis Depressive disorders spectrum analysis
Coefficient [95% confidence interval] Coefficient [95% confidence interval]
Arm characteristics
RCT (Ref=Observational) 4.59 [2.61 to 6.56] 2.45 [0.97 to 3.93]
Scale (Ref=HAM-21)
HAMD-17 22.32 [23.03 to 21.61] 21.66 [22.29 to 21.03]
MADRS 21.26 [22.62 to 0.09] 21.34 [22.10 to 0.57]
Treatment (Ref=Fluoxetine)
Placebo 23.35 [23.97 to 22.74] 23.42 [23.93 to 22.92]
Venlafaxine 2.51 [1.88 to 3.14] 2.25 [1.81 to 2.70]
Double blind study (Ref=No) 25.21 [26.85 to 23.57] 23.37 [24.65 to 22.09]
Placebo design study (Ref=No) 24.54 [25.50 to 23.58] 23.54 [24.21 to 22.86]
Year of publication 0.07 [0.01 to 0.13] 0.10 [0.05 to 0.15]
Duration 0.27 [0.14 to 0.40] 0.17 [0.11 to 0.23]
Number of follow up assessments 0.33 [0.11 to 0.55] 0.26 [0.13 to 0.39]
Exclusion of placebo responders 20.27 [21.06 to 0.52] 20.08 [20.71 to 0.54]
Type of analysis PP (Ref=ITT with LOCF) 2.52 [1.45 to 3.6] 2.55 [1.87 to 3.23]
Patient type (Ref=Inpatients)
Outpatients 1.81 [0.88 to 2.72] 2.81 [2.18 to 3.43]
Outpatients in primary care 3.73 [2.37 to 5.09] 3.69 [2.59 to 4.80]
Patient characteristics
Mean age 20.16 [20.26 to 20.07] 20.05 [20.11 to 0.01]
Gender 0.00 [20.03 to 0.04] 0.01 [20.02 to 0.04]
Baseline severity 0.78 [0.71 to 0.84] 0.83 [0.78 to 0.88]
Results are expressed in points of the standardised difference in mean.
Ref: reference.
PP: Per Protocol.
ITT with LOCF: Intention To Treat with Last Observation Carried Forward.
doi:10.1371/journal.pone.0020811.t003
Table 2.Cont.
Main analysis (Major depressive disorder) Second analysis (depressive disorder spectrum)
Randomised Controlled
Trials Observational Trials
Randomised
Controlled Trials Observational Trials
Characteristics of trial
participants
Number of patients entering
analysis
11035 6757 12405 15753
Age
Mean (NA=8) 42.5 46.9 (NA=9) 42.5 47.9
SD (NA=39) 7.4 (NA=1) 6.9 (NA=46) 7.4 (NA=1) 7
Proportion of women (%) (NA=7) 67.8 68.7 (NA=7) 66.9 70.1
Baseline severity (% of the scale)
Mean (NA=2) 45.0 42.3 (NA=2) 44.1 41.9
SD (NA=39) 7.8 (NA=1) 9.5 (NA=43) 7.9 (NA=1) 9.4
Quality score is computed out of 100 points from the two Joanna Brigs Institute instruments.
Data shown here as NA (Non Available or Missing data) are imputed in the meta-regression models.
ITT with LOCF: Intention To Treat with Last Observation Carried Forward.
doi:10.1371/journal.pone.0020811.t002
RCT vs. Observational Studies on Antidepressants
PLoS ONE | www.plosone.org 6 June 2011 | Volume 6 | Issue 6 | e20811remarkable that this last value is close to the coefficient of 4.59
obtained in the main analysis. This study is in fact a randomized
controlled study designed to measure effectiveness, which is not
unlike an observational study.
We also performed: 1/a post hoc analysis (without placebo arms)
adding the variable treatment dosage to assess its impact; it did not
prove to be statistically significant, whereas estimations of other
coefficients were unchanged; 2/a post hoc analysis, excluding three
studies suspected of multiple publications, and we found no
difference in our results; 3/a post hoc analysis using the standard
deviation of the pre/post treatment difference as a standardization
unit (i.e. (Post score-Pre score)/SD of the score difference) which
produced similar results.
Discussion
Summary of evidence
Our results highlight a difference in patient response to
treatment between RCTs and observational studies with a larger
estimate in RCTs.
Certain design factors associated with treatment response,
already reported in the literature, were here evidenced in the
context of a study including both RCTs and observational studies.
This can be considered as an element of external validity as
regards the present study. Treatment and placebo mean responses
increase with depression severity [2,3], with duration of treatment,
with the number of follow up assessments [5] and with the year of
publication of the study [4]. Per-protocol analysis gives larger
response estimates when compared to intention to treat analysis.
We also found that mean antidepressant response decreases with
placebo design and with blinded design. This could have a
relationship with patient expectations for treatment effect [6], or
rather with clinician expectations, since the depression scales
considered here were clinician-version evaluations. Independently
from baseline severity, inpatient mean treatment response is
smaller compared to primary care patients or outpatients. This
could relate to the higher levels of psychiatric comorbidities
presented by inpatients. Venlafaxine and fluoxetine obtain a better
response than placebo, and venlafaxine a better response than
fluoxetine [16] even if it is small [25].
Perspective
Randomized controlled trials are considered as the gold
standard in the hierarchy of research designs for evaluating the
efficacy and safety of a treatment intervention. Two major benefits
are expected from randomization [26]: unbiased allocation of
treatment, and application of statistical theory on the basis of
random sampling which makes it possible to infer the specific
treatment effect, especially when there is a blinded allocation of
treatments. Another important argument in favor of RCTs can be
derived from their methodological characteristics: they are so well
documented and they rely on so simple a statistical paradigm that
they can resist the major financial conflicts of interest inherent in
the evaluation of pharmaceuticals. It can be recalled that the
global pharmaceuticals market represents about 1% of the world
gross domestic product [27].
Nevertheless, RCTs are criticised. First they are expensive, and
indeed increasingly so. This reduces their feasibility and has
potential consequences on the prices of new medication which are
likely to become incompatible with the restrictions in health care
Figure 2. Funnel plots are presented for all types of arms: the left-hand plot concerns antidepressant arms in randomized
controlled trials (RCTs), the middle plot concerns placebo arms in RCTs and the right-hand plot concerns antidepressant arms in
observational studies. For each arm, the x-axis presents the standardised pre/post treatment difference in mean and the y-axis presents the
number of patients analysed. The black dots represent studies in the main analysis and red dots studies added in the depressive disorders spectrum
analysis.
doi:10.1371/journal.pone.0020811.g002
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the field of antidepressants where trials are still performed against
a placebo, although older antidepressants are widely considered to
be the best control alternative [28]. Even if such studies are
justified, approved by ethics committees and required by
regulatory agencies, at patient or investigator level the design
can limit inclusion of patients needing active treatment. Thirdly, in
the field of antidepressants, the ability of a double-blind design to
preserve the benefit of randomisation is disputed [29]. Finally, they
do not closely reflect clinical practice and lack of external validity
[9,30].
Observational studies have better external validity and they have
other characteristics that make them useful sources of evidence, in
that they tend to last longer and to enrol more patients than do
randomized trials [31]. Statistical modelling should enable adjust-
ment on known [32] or any potential [33] confounding factors, thus
increasing the internal validity of such studies.
Only two naturalistic studies, both in a post hoc analysis, have
explored the question of the link between antidepressant efficacy and
effectiveness. In a retrospective analysis of a cohort of 1,014 inpatients
[34], patients eligible (on the basis of classic inclusion criteria) for a
RCTandpatientsnoteligible differed significantly onseveralbaseline
measures and final Global Assessment of Functioning scores but not
on any other outcome measures such as depression rating scales.
However, this study only investigated inpatients (a more homogenous
population) and the analysis was not adjusted on prognosis factors at
baseline or on treatment associated (psychotherapy, use of a
pharmacological augmentation strategy).
In another similar analysis applied to the outpatient STAR-D
cohort [10], the authors found that patients eligible for a RCT had
a better response which persisted even after adjustments for
baseline differences. The design of this study is more efficient in
controlling for confounders such as psychotherapy and pharma-
cological augmentation strategies.
Thus the place of observational studies in treatment effect
assessment is open to discussion. Our study is of interest in this
debate because we found a difference in response to antidepres-
sants between the two approaches, with larger estimates in RCTs
than in observational studies. However, this difference does not
constitute a clear clinical difference. The National Institute for
Clinical Excellence has suggested that at least a 3-point difference
is needed on the Hamilton scale to claim a clinically significant
effect [35]. This corresponds to a variation of 5.8 points on our
standardized score, whereas the adjusted mean difference here is
4.59. Nevertheless the small clinical relevance of this difference
should be put in perspective, and it is remarkable that it is very
similar to the difference between the antidepressant and placebo
responses estimated in the present study. Thus, being a little bit
provocative, two points of view are possible: 1/if one believes that
antidepressants have greater effect than placebos, then there is
indeed a large difference between treatment response as estimated
by observational studies and treatment effect estimated by RCTs;
2/if one considers that antidepressants are not actually more
efficient than placebos [36] the difference between observational
studies and randomized controlled trial can also be considered as
small, but no longer relevant.
Furthermore, these two thresholds for clinical significance (the
NICE threshold and the difference between placebo and
antidepressant) can be used to interpret all coefficients estimated
with our model.
Limitations
The limitations of a meta-analysis are linked to the limitations of
the individual studies included [37]. As we used observational
trials and the arms of the RCTs were separated, our work has a
level of evidence coherent with observational study meta-analysis.
Since confounders could be present when comparing treatment
effect in observational studies and in RCTs, we used a meta-
regression. However this approach can also present limitations
[38]. It is more likely to detect effects at study level, but it can lead
to misinterpretations at patient level, where an aggregation bias
can occur, and this cannot be investigated without individual
patient data [39]. Thus results relating to patient characteristics
such as gender, severity, and age should be interpreted cautiously.
Our choice of a standardisation of pre/post treatment scores by
multiplying the scores by 100 and dividing them by the possible
range of the instrument could be criticised or at least appear as
unconventional compared to the more classic use of a standard
deviation of the pre/post treatment difference as a standardization
unit (i.e. (Post score-Pre score)/SD of the score difference).
Nevertheless, we support our a priori choice for four principal
reasons relating to our objective: 1/the standard deviation of the
score difference (i.e. the variability) is not solely due to differences
on the scale, it is also due to patient heterogeneity in the studies.
This could lead mathematically to an underestimation of classic
outcomes such as (Post score-Pre score)/(SD of the score
difference) in observational studies (where there is great hetero-
geneity) as compared to RCTs. 2/it appears as the simplest
statistic to interpret for clinicians (% of variation of a scale) 3/as we
had to impute variance for several standard deviations of the score
difference, the imputed data were not used for the calculation of
our principal outcome. Indeed, in meta-analysis, multiple
imputation is frequent for the variance of an outcome [40] but it
could be problematic if it directly concerns the outcome 4/the use
of effect size is criticised in the literature [17,18].
Thus, taking the precaution to consider the depression scale
used as an explanatory variable in our regression model, we are
confident in this outcome. In addition, we performed a post hoc
sensitivity analysis using a classic method to standardise scales. It
led to the same conclusion (i.e. there is a larger estimate of
treatment response in RCTs).
A publication bias, which could involve a differential between
randomized controlled trials and observational studies, might
account for some of the effect we observed. However, the funnel
plots of antidepressant response suggest that selective reporting did
not lead to an overestimation of D in RCTs or in observational
studies. Conversely, in randomized controlled trials on antide-
pressants against placebo, the funnel plot of the placebo response is
asymmetrical, which illustrates a known publication bias [1] with
an underestimation of placebo response in these studies.
A four-week observational study in which the mean pre-post
treatment difference is small [23] could have led to an
overestimation of the difference between observational studies
and RCTs. However it met our inclusion criteria and there is
basically no reason to remove it. One could object that so short a
study duration is not sufficient for an observational study. In fact,
the small effect makes sense from a clinical point of view, because
one month is typically the time lapse clinicians choose to
discontinue an ineffective treatment [41].
Conclusions
Implications for practice. In their day-to-day practice,
clinicians and health authorities generally evaluate the
effectiveness of new medication from RCTs. In the field of
antidepressants it should be known that, as already demonstrated
on non-antidepressant drug studies [42], larger efficacy estimates
can be expected in optimal experimental conditions than the
effectiveness estimates obtained in real-word setting. This could
RCT vs. Observational Studies on Antidepressants
PLoS ONE | www.plosone.org 8 June 2011 | Volume 6 | Issue 6 | e20811have implications as to which patients should be treated by the
clinician, and what costs the health authority should cover.
Implications for research. Observational studies should be
considered as a necessary complement to randomized controlled
trials. Phase IV studies should not be restricted to the study of the
safety of a product, they should also study effectiveness.
Describing the design factors that can modify measures of
antidepressant response will help researchers to choose more
appropriate designs and to find a balance between internal and
external validity. This has ethical implications because patient
improvement is linked to the design. Our work could help to draft
guidelines defining what design antidepressant efficacy and
effectiveness trials should adopt.
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